West Pharmaceutical Services, Inc. (BVMF:W2ST34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 107.87B +25.8% |
| Revenue (ttm) | 16.80B +11.2% |
| Net Income | 2.83B +16.2% |
| EPS | 39.03 +17.4% |
| Shares Out | n/a |
| PE Ratio | 38.10 |
| Forward PE | 34.31 |
| Dividend | 0.09 (0.20%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 47 |
| Average Volume | 120 |
| Open | 45.98 |
| Previous Close | n/a |
| Day's Range | 45.15 - 45.98 |
| 52-Week Range | 33.51 - 48.04 |
| Beta | 1.17 |
| RSI | 63.58 |
| Earnings Date | Apr 23, 2026 |
About BVMF:W2ST34
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhanc... [Read more]
Financial Performance
In 2025, BVMF:W2ST34's revenue was $3.07 billion, an increase of 6.25% compared to the previous year's $2.89 billion. Earnings were $493.70 million, an increase of 0.20%.
Financial numbers in USD Financial StatementsNews
West Pharma says operations recovering after cyberattack
West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack earlier this month disrupted manufacturing and logistics globally.
West Pharmaceutical reports ‘significant progress’ in post-cyberattack recovery
West Pharmaceutical (WST) provided a cyberattack update, saying the company continues to make significant progress in restoring its operations globally. Regarding the proprietary products segment, Wes...
West Pharmaceutical Services Transcript: Bank of America Global Healthcare Conference 2026
A recent cybersecurity breach was contained with minimal disruption, and operations are being restored methodically. Strong Q1 results were driven by robust demand for HVP components, GLP-1s, and regulatory changes, supporting raised guidance and long-term growth expectations.
West Pharmaceutical Services Transcript: AGM 2026
The meeting covered board elections, executive compensation, auditor ratification, and a shareholder proposal for an independent board chair, which was not approved. All director nominees were reelected and executive pay was endorsed by a majority.
West to Participate in Upcoming Investor Conferences
EXTON, Pa., April 28, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pres...
West Pharmaceutical price target raised to $315 from $285 at Morgan Stanley
Morgan Stanley raised the firm’s price target on West Pharmaceutical (WST) to $315 from $285 and keeps an Equal Weight rating on the shares.
West Pharmaceutical price target raised to $310 from $275 at Barclays
Barclays raised the firm’s price target on West Pharmaceutical (WST) to $310 from $275 and keeps an Equal Weight rating on the shares. The firm updated the company’s model following…
West Pharmaceutical price target raised to $400 from $375 at Citi
Citi raised the firm’s price target on West Pharmaceutical (WST) to $400 from $375 and keeps a Buy rating on the shares.
West Pharmaceutical price target raised to $390 from $320 at Evercore ISI
Evercore ISI raised the firm’s price target on West Pharmaceutical (WST) to $390 from $320 and keeps an Outperform rating on the shares.
Early notable gainers among liquid option names on April 23rd
Notable gainers among liquid option names this morning include United Rentals (URI) $953.00 +150.21, Texas Instruments (TXN) $276.42 +40.11, West Pharmaceutical (WST) $315.56 +41.14, ON Semiconductor ...
West Pharmaceutical Services Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and 47% higher adjusted EPS, driven by strong HVP component and biologics demand. Full-year guidance was raised for both revenue and EPS, with operational excellence and global regulatory trends supporting continued momentum.
West Pharmaceutical Services Slides: Q1 2026
West Pharmaceutical Services has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
West Pharmaceutical Services Earnings release: Q1 2026
West Pharmaceutical Services released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
West Pharmaceutical Services Quarterly report: Q1 2026
West Pharmaceutical Services has published its Q1 2026 quarterly earnings report on April 23, 2026.
West Pharma lifts 2026 profit forecast on strong demand for medical equipment
West Pharmaceutical on Thursday raised its annual profit and revenue forecasts after beating estimates for first-quarter results, betting on strong demand for its proprietary products that include sy...
West Reports First-Quarter 2026 Results
Strong Start to the Year and Raising Full-Year Revenue and EPS guidance EXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, hig...
West Pharmaceutical price target raised to $275 from $265 at Barclays
Barclays raised the firm’s price target on West Pharmaceutical (WST) to $275 from $265 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life…
West to Host First-Quarter 2026 Conference Call
EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will relea...
West Pharmaceutical expands Damastown, Dublin facility
West Pharmaceutical (WST) Services announced the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West’s contract services...
West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
EXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of it...
West Pharmaceutical Services Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Strong 2025 momentum sets up 2026 for 5%-7% growth, driven by non-GLP-1 business and capacity expansion. Annex 1 regulation and biologics pipeline fuel multi-year growth, while conservative GLP-1 guidance leaves room for upside.
West Pharmaceutical Services Proxy statement: Proxy Filing
West Pharmaceutical Services filed a proxy statement on March 12, 2026, providing details for shareholder voting and corporate governance matters.
West Pharmaceutical Services Proxy statement: Proxy Filing
West Pharmaceutical Services filed a proxy statement on March 12, 2026, providing details for shareholder voting and corporate governance matters.
West Pharmaceutical Services Transcript: Barclays 28th Annual Global Healthcare Conference
Leadership transition is underway with a strong executive team and external search. Growth is driven by biologics, biosimilars, and GLP-1s, with robust demand and capacity expansion. Margin improvement is expected from product mix and SmartDose divestiture, while regulatory changes and innovation support a long runway for high-value products.
West Pharma CEO Eric Green to retire after 11 years at the helm
West Pharmaceutical's chief executive Eric Green said on Monaday he plans to retire once the company finds his successor, ending an 11-year run at the helm.